Your browser is no longer supported. Please, upgrade your browser.
Settings
PFNX Pfenex Inc. daily Stock Chart
PFNX [NYSE]
Pfenex Inc.
Index- P/E- EPS (ttm)-0.91 Insider Own0.30% Shs Outstand32.96M Perf Week5.43%
Market Cap319.71M Forward P/E53.89 EPS next Y0.18 Insider Trans- Shs Float29.18M Perf Month42.02%
Income-28.80M PEG- EPS next Q-0.09 Inst Own84.20% Short Float1.63% Perf Quarter39.57%
Sales20.10M P/S15.91 EPS this Y-27.80% Inst Trans0.56% Short Ratio2.71 Perf Half Y97.56%
Book/sh1.64 P/B5.91 EPS next Y131.60% ROA-37.50% Target Price17.00 Perf Year96.75%
Cash/sh1.26 P/C7.69 EPS next 5Y44.20% ROE-48.20% 52W Range3.13 - 10.16 Perf YTD204.08%
Dividend- P/FCF- EPS past 5Y-29.90% ROI-64.70% 52W High-4.53% Beta2.34
Dividend %- Quick Ratio4.80 Sales past 5Y4.50% Gross Margin73.80% 52W Low209.90% ATR0.55
Employees78 Current Ratio4.80 Sales Q/Q-33.30% Oper. Margin- RSI (14)74.18 Volatility7.12% 6.38%
OptionableYes Debt/Eq0.01 EPS Q/Q41.50% Profit Margin- Rel Volume1.23 Prev Close9.29
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume175.76K Price9.70
Recom- SMA2025.27% SMA5041.12% SMA20072.98% Volume212,477 Change4.41%
Aug-09-16Reiterated Mizuho Buy $22 → $18
May-24-16Reiterated Barclays Overweight $28 → $14
May-18-15Initiated Barclays Overweight $28
Feb-17-15Reiterated Mizuho Buy $12 → $16
Sep-16-19 04:05PM  Pfenex to Present at the Cantor Healthcare Conference GlobeNewswire
Sep-10-19 04:05PM  Pfenex to Participate in the Oppenheimer Fall Summit GlobeNewswire
Sep-05-19 04:05PM  Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals GlobeNewswire +6.65%
Sep-04-19 04:05PM  Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board GlobeNewswire
Aug-17-19 06:24PM  Edited Transcript of PFNX earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 07:30PM  Pfenex (PFNX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:10PM  Pfenex Announces Appointment of New Board Member, Lorianne Masuoka, M.D. GlobeNewswire
04:05PM  Pfenex Reports Second Quarter 2019 Results and Provides Business Update GlobeNewswire
Aug-01-19 10:33AM  Will Pfenex (PFNX) Report Negative Earnings Next Week? What You Should Know Zacks +9.18%
08:10AM  Pfenex and Arcellx Announce a Development, Evaluation and License Agreement GlobeNewswire
Jul-25-19 04:10PM  Pfenex to Announce Second Quarter 2019 Financial Results on August 8 GlobeNewswire
Jul-19-19 12:42PM  Those Who Purchased Pfenex (NYSEMKT:PFNX) Shares Three Years Ago Have A 23% Loss To Show For It Simply Wall St.
Jun-25-19 08:59PM  Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX) Insider Monkey
Jun-20-19 07:52AM  Pfenex Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-18-19 05:45PM  Edited Transcript of PFNX earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-05-19 04:05PM  Pfenex to Participate at the JMP Securities Life Sciences Conference GlobeNewswire
May-30-19 08:01AM  Pfenex and Alvogen Announce European Medicines Agency Accepts Marketing Authorization Application for PF708 GlobeNewswire
May-21-19 08:06AM  Pfenex Inc. (PFNX) Shares March Higher, Can It Continue? Zacks
May-09-19 07:35PM  Pfenex (PFNX) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM  Pfenex Reports First Quarter 2019 Results and Provides Business Update GlobeNewswire
May-02-19 10:33AM  Pfenex (PFNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-25-19 04:05PM  Pfenex to Announce First Quarter 2019 Financial Results on May 9 GlobeNewswire
Apr-23-19 08:05AM  Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board GlobeNewswire
Apr-11-19 08:05AM  Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act GlobeNewswire
Mar-27-19 04:05PM  Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference GlobeNewswire
Mar-26-19 04:05PM  Pfenex to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-18-19 04:05PM  Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference GlobeNewswire
08:05AM  Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer GlobeNewswire
Mar-15-19 08:29AM  Will Pfenex Continue to Surge Higher? Zacks
Mar-13-19 11:40PM  Edited Transcript of PFNX earnings conference call or presentation 11-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-11-19 05:30PM  Pfenex (PFNX) Reports Q4 Loss, Misses Revenue Estimates Zacks +10.80%
04:05PM  Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update GlobeNewswire
11:54AM  Are Insiders Buying Pfenex Inc. (NYSEMKT:PFNX) Stock? Simply Wall St.
Mar-06-19 04:05PM  Pfenex Licensee Successfully Completes a Phase 3 Study and Enters Registration for Pneumosil® GlobeNewswire -7.61%
Mar-04-19 08:05AM  Pfenex Announces Appointment of New Board Member, Magda Marquet, Ph.D. GlobeNewswire -8.91%
Feb-28-19 08:05AM  Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW GlobeNewswire +7.42%
Feb-27-19 04:05PM  Pfenex to Participate at Two Investor Conferences in March GlobeNewswire
Feb-25-19 04:05PM  Pfenex to Host Conference Call and Webcast Reporting Fourth Quarter Financial Results on Monday, March 11th GlobeNewswire
Feb-19-19 08:05AM  Pfenex Announces FDA Acceptance of NDA for PF708 GlobeNewswire
Dec-10-18 08:00AM  Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis GlobeNewswire +10.06%
Nov-26-18 08:20AM  Market Trends Toward New Normal in Suburban Propane Partners, Sanchez Midstream Partners LP, Imperial Oil, Pfenex, National Commerce, and Yuma Energy Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -11.04%
Nov-20-18 07:32AM  Edited Transcript of PFNX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 04:05PM  Pfenex Reports Third Quarter Results and Provides Business Update GlobeNewswire
Oct-25-18 04:05PM  Pfenex to Host Conference Call and Webcast Reporting Third Quarter Financial Results on Wednesday, November 7 GlobeNewswire
Oct-01-18 04:05PM  Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules GlobeNewswire
Sep-21-18 04:29PM  Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-11-18 08:00AM  Pfenex Names Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer GlobeNewswire
Sep-04-18 08:00AM  Pfenex to Present at the Liolios 7th Annual Gateway Conference GlobeNewswire
Aug-23-18 09:50PM  Edited Transcript of PFNX earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 04:05PM  Pfenex Announces Departure of Chief Medical and Scientific Officer Dr. Hubert Chen GlobeNewswire
Aug-08-18 04:05PM  Pfenex Reports Second Quarter Results and Provides Business Update GlobeNewswire
02:30PM  Pfenex, Inc. to Host Earnings Call ACCESSWIRE
Jul-25-18 04:05PM  Pfenex to Host Conference Call and Webcast Reporting Second Quarter Financial Results on Wednesday, August 8 GlobeNewswire
Jul-12-18 08:00AM  Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114) GlobeNewswire
Jun-22-18 05:00PM  Pfenex Set to Join Russell 2000® Index GlobeNewswire
Jun-14-18 04:15PM  Pfenex to Present at the JMP Securities 2018 Life Science Conference GlobeNewswire
Jun-11-18 04:05PM  Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo® GlobeNewswire
May-29-18 09:10AM  Pfenex Announces Closing of Public Offering of 7,820,000 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire -9.33%
May-23-18 09:10AM  Pfenex Announces Pricing of Offering of 6,800,000 Shares of Common Stock GlobeNewswire -13.77%
May-22-18 04:23PM  Pfenex Announces Offering of Common Stock GlobeNewswire
May-18-18 01:52PM  Edited Transcript of PFNX earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents -7.12%
May-14-18 04:02PM  Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018 PR Newswire -10.29%
May-10-18 04:02PM  Pfenex Reports First Quarter 2018 Results and Provides Business Update PR Newswire
Apr-30-18 04:15PM  Pfenex to Report First Quarter 2018 Results and Provide Business Update on Thursday, May 10th PR Newswire
Apr-18-18 05:05PM  BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo Reuters
05:00PM  Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo® PR Newswire
Mar-16-18 01:11PM  Edited Transcript of PFNX earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 04:02PM  Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update PR Newswire
12:30PM  Pfenex, Inc. to Host Earnings Call ACCESSWIRE
07:26AM  One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX) Simply Wall St.
Mar-13-18 04:15PM  Pfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference PR Newswire
Mar-08-18 04:15PM  Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018 PR Newswire
Feb-27-18 04:15PM  Pfenex Inc. to Present at Barclay's 2018 Global Healthcare Conference PR Newswire
Jan-04-18 08:00AM  Pfenex Names Susan A. Knudson as Chief Financial Officer PR Newswire
Jan-01-18 09:09AM  Pfênex, Inc. :PFNX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-19-17 08:00AM  Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals PR Newswire +62.50%
Nov-13-17 08:59AM  Edited Transcript of PFNX earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents -9.49%
Nov-10-17 12:46PM  ETFs with exposure to Pfênex, Inc. : November 10, 2017 Capital Cube
Nov-09-17 06:15PM  Pfenex Inc. to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
04:05PM  Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update PR Newswire
12:10PM  Pfenex, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-17 04:05PM  Pfenex to Report Third Quarter 2017 Results and Provide Business Update on Thursday, November 9, 2017 PR Newswire
Oct-26-17 10:42AM  ETFs with exposure to Pfênex, Inc. : October 26, 2017 Capital Cube
Oct-16-17 09:58AM  ETFs with exposure to Pfênex, Inc. : October 16, 2017 Capital Cube
Sep-28-17 10:18AM  ETFs with exposure to Pfênex, Inc. : September 28, 2017 Capital Cube
Sep-27-17 08:59AM  Pfênex, Inc. :PFNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017 Capital Cube
Sep-19-17 07:00AM  Pfenex To Present at the Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017 PR Newswire
Sep-07-17 05:45PM  Pfenex Announces Management Changes PR Newswire
Sep-01-17 07:00AM  Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules PR Newswire
Aug-29-17 06:00AM  Pfenex To Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017 PR Newswire
Aug-23-17 08:00AM  Pfenex To Present at the 6th Annual Liolios Gateway Conference on September 6th, 2017 PR Newswire
Aug-13-17 03:31AM  Edited Transcript of PFNX earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 04:05PM  Pfenex Reports Second Quarter 2017 Results and Provides Business Update PR Newswire
Aug-03-17 06:00AM  Pfenex Names Eef Schimmelpennink Chief Executive Officer PR Newswire
Jul-25-17 05:00PM  Pfenex To Report Second Quarter 2017 Results and Provide Business Update on Wednesday, August 9, 2017 PR Newswire
Jul-13-17 04:28PM  ETFs with exposure to Pfênex, Inc. : July 13, 2017 Capital Cube
Jun-26-17 04:41PM  ETFs with exposure to Pfênex, Inc. : June 26, 2017 Capital Cube
Jun-08-17 08:00AM  Pfenex to Present at the 2017 JMP Healthcare Conference PR Newswire
Jun-02-17 02:23PM  ETFs with exposure to Pfênex, Inc. : June 2, 2017 Capital Cube
Jun-01-17 09:38AM  Pfênex, Inc. :PFNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017 Capital Cube
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.